{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Patutina O"],"funding":["Russian state-funded project","Russian Science Foundation"],"pagination":["122"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12845401"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["18(1)"],"pubmed_abstract":["<b>Background and Objectives:</b> Aggressive cancer development is characterized by rapid tumor growth and progressive immune dysfunction. Tumor-derived microRNAs (miRNAs) emerge as master regulators of both malignant transformation and immune evasion, making them promising therapeutic targets. Using the highly aggressive CT-26 peritoneal adenomatosis model, this study explored the potential of selective miRNA inhibition to simultaneously suppress tumor growth and overcome immunosuppression. <b>Methods and Results:</b> Our results revealed that inhibition of miR-155, miR-21, and miR-17 by methylsulfonyl phosphoramidate (mesyl) oligonucleotides exhibited markedly different therapeutic profiles. miR-155 inhibition demonstrated minimal efficacy. miR-21 suppression provided early tumor regress"],"journal":["Pharmaceutics"],"pubmed_title":["Targeted Inhibition of Oncogenic microRNAs miR-21, miR-17, and miR-155 Suppresses Tumor Growth and Modulates Immune Response in Colorectal Cancer."],"pmcid":["PMC12845401"],"funding_grant_id":["19-74-30011","125012300659-6"],"pubmed_authors":["Awad M","Zenkova M","Gladkikh D","Savin I","Zhukov S","Miroshnichenko S","Kupryushkin M","Markov O","Sen'kova A","Vlassov V","Patutina O","Seroklinova E","Maslov M"],"additional_accession":[]},"is_claimable":false,"name":"Targeted Inhibition of Oncogenic microRNAs miR-21, miR-17, and miR-155 Suppresses Tumor Growth and Modulates Immune Response in Colorectal Cancer.","description":"<b>Background and Objectives:</b> Aggressive cancer development is characterized by rapid tumor growth and progressive immune dysfunction. Tumor-derived microRNAs (miRNAs) emerge as master regulators of both malignant transformation and immune evasion, making them promising therapeutic targets. Using the highly aggressive CT-26 peritoneal adenomatosis model, this study explored the potential of selective miRNA inhibition to simultaneously suppress tumor growth and overcome immunosuppression. <b>Methods and Results:</b> Our results revealed that inhibition of miR-155, miR-21, and miR-17 by methylsulfonyl phosphoramidate (mesyl) oligonucleotides exhibited markedly different therapeutic profiles. miR-155 inhibition demonstrated minimal efficacy. miR-21 suppression provided early tumor regress","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Jan","modification":"2026-06-16T03:11:27.313Z","creation":"2026-06-16T03:07:11.164Z"},"accession":"S-EPMC12845401","cross_references":{"pubmed":["41599229"],"doi":["10.3390/pharmaceutics18010122"]}}